Granted Patent B2

US 12,595,512 · App. 18/812,678 · Granted Apr 7, 2026

Inventors: Tobin Dickerson (San Marcos, CA); Bradford Taft (San Francisco, CA); Byung-In Lee (Encinitas, CA)

Assignee: MiNDERA Corporation

C12Q1/6883C12Q1/6869C12Q2600/106C12Q2600/158

Abstract

Claims (23)

1 . A method of treating a human subject with psoriasis, comprising:

(a) obtaining RNA molecules from a lesional skin of the human subject with psoriasis by applying a microneedle device to the lesional skin of the human subject, wherein the microneedle device comprises one or more nucleic acids probes that are capable of hybridizing to the RNA molecules, wherein the human subject has not been administered an IL-23 inhibitor prior to the obtaining the RNA molecules;

(b) assaying the obtained RNA molecules in order to identify expression levels of MTCO1P12, MTATP6P1, CLSTN1, PDPN, LDLRAD2, AL158847.1, GSTM3, CRCT1, LCE6A, ITM2C, CRTAP, UCN2, TP63, EREG, GLRX, NREP, FCHSD1, DST, HOXA9, LAMB1, MXRA5, ZNF395, SNAI2, NPR2, SPAG8, GPSM1, TP53111, PACSIN3, TYR, USP2, PPIF, AGAP11, AL136982.1, AL136982.4, AL136982.2, AL136982.5, MGMT, HOXC6, PRIM1, LLPH, HAL, TXNRD1, AC089983.1, EID3, RNASE7, DAD1, JAG2, KIFC3, SMPD3, and PLCD3, by sequencing the obtained RNA molecules;

(c) predicting that the human subject with psoriasis will be responsive to the IL-23 inhibitor based on the expression levels in (b); and

(d) based on (c), administering the IL-23 inhibitor to the human subject.

2 . The method of claim 1 , wherein a positive predictive value (PPV) of the method is greater than 90%.

3 . The method of claim 1 , wherein a positive predictive value (PPV) of the method is greater than 95%.

4 . The method of claim 1 , wherein a negative predictive value (NPV) of the method is greater than 50%.

5 . The method of claim 1 , wherein the human subject with psoriasis has a Psoriasis Area and Severity Index (PASI) score of at least 5.

6 . The method of claim 5 , wherein the PASI score decreases by at least 75% after treating with the IL-23 inhibitor.

7 . The method of claim 1 , wherein the IL-23 inhibitor is a biologic.

8 . The method of claim 1 , wherein the IL-23 inhibitor comprises an antibody.

9 . The method of claim 1 , wherein the IL-23 inhibitor is at least one drug selected from the group consisting of tildrakizumab, guselkumab, ustekinumab, and risankizumab.

10 . The method of claim 1 , wherein the IL-23 inhibitor is at least one drug selected from the group consisting of tildrakizumab, guselkumab, and risankizumab.

11 . The method of claim 1 , wherein the IL-23 inhibitor is at least one drug selected from the group consisting of tildrakizumab and guselkumab.

12 . The method of claim 1 , wherein the RNA molecules are mRNA molecules.

13 . The method of claim 1 , wherein (c) comprises applying a trained algorithm to the expression levels in (b) to predict that the human subject with psoriasis will be responsive to the IL-23 inhibitor, wherein an algorithm is trained using transcriptome profiles of responders and non-responders to the IL-23 inhibitor to provide the trained algorithm.

14 . The method of claim 1 , wherein a nucleic acids probe of the one or more nucleic acids probes comprises a homopolymeric sequence.

15 . The method of claim 14 , wherein the homopolymeric sequence comprises thymine or uracil.

16 . The method of claim 14 , wherein the homopolymeric sequence comprises two or more consecutive thymine residues.

17 . The method of claim 14 , wherein the homopolymeric sequence comprises at least 10 consecutive thymine residues.

18 . The method of claim 14 , wherein the homopolymeric sequence comprises at least 20 consecutive thymine residues.

19 . The method of claim 12 , wherein the one or more nucleic acids probes bind to poly-A tails of the mRNA molecules.

Assignments (1)

Continuity (5)

References Cited (169)